GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.7 USD | +1.35% |
|
+0.67% | -20.13% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 15 M€ | -1.62% | - | |
| 0.08% | 104 M€ | +4.01% | - | |
| 0.06% | 11 M€ | +1.95% | - | |
| 0.06% | 6 M€ | +3.89% | ||
| 0.05% | 17 M€ | +3.59% | - | |
| 0.04% | 55 M€ | +0.75% | - | |
| 0.03% | 25 M€ | +16.34% | - | |
| 0.03% | 248 M€ | +11.05% | - | |
| 0.03% | 8 M€ | +1.08% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.01% | 32 M€ | +4.30% | - | |
| 7.69% | 132 M€ | +8.76% | - | |
| 11.65% | 30 M€ | +9.43% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.13% | 80.61B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.77% | 248B | |
| -2.00% | 219B | |
| +10.91% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
